<div id="readability-page-1"><article>SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the first quarter 2026 on Wednesday, May 13, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss recent developments and highlights as well as the Company’s financial results.Conference Call Details and Webcast Link InstructionsTo access the live webcast, please click here or visit the “Upcoming Events” section of the Investor Relations page of Omeros’ website.A replay of the call will be available for 90 days in the “Archived Events” section of the Investor Relations page of Omeros’ website.As Omeros continues to transition to a new earnings call platform (hosted by Q4 Inc.), please allow extra time to log in prior to the start of the call.About Omeros CorporationOmeros is an innovative biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for both large-market and orphan indications, with a focus on complement-mediated diseases, cancers, and addictive or compulsive disorders. Omeros’ lead complement inhibitor YARTEMLEA® (narsoplimab-wuug), which targets the lectin pathway’s effector enzyme MASP-2, is FDA-approved and commercially available in the U.S. for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adult and pediatric patients aged two years and older. A marketing authorization application seeking approval of YARTEMLEA for TA-TMA is currently under review at the European Medicines Agency. OMS1029, Omeros’ long-acting MASP-2 inhibitor, has successfully completed Phase 1 clinical trials.Under a recently announced asset purchase and licensing agreement, Novo Nordisk acquired global rights to zaltenibart (formerly OMS906), an inhibitor of MASP-3, the alternative pathway’s key activator, which is in clinical development for PNH and other alternative pathway indications, along with associated intellectual property and related assets. Omeros’ pipeline also includes OMS527, a phosphodiesterase 7 inhibitor in clinical development for cocaine use disorder, which is fully funded by the National Institute on Drug Abuse, and a growing portfolio of novel recombinant antibodies targeting multidrug-resistant organisms and novel molecular and cellular therapeutic programs for oncology. For more information about Omeros and its programs, visit www.omeros.com.<img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjA1MTE1NDY2NThyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjA1MTE1NDY2NThyMQ"/>View source version on businesswire.com: https://www.businesswire.com/news/home/20260511546658/en/Jennifer Cook Williams Cook Williams Communications, Inc. Investor and Media Relations IR@omeros.comSource: Omeros Corporation</article></div>

OMER

SBIO

LABU

ARKG

Omeros Corporation (NASDAQ: OMER) will announce its first quarter financial results for 2026 on May 13, 2026, after market close. A conference call and webcast will follow at 4:30 p.m. ET to discuss the results and recent developments. Omeros is a biotechnology company focused on developing therapeutics for complement-mediated diseases and has FDA-approved products, including YARTEMLEA® for TA-TMA. The company is also advancing its pipeline, including OMS1029 and OMS527, with various partnerships and ongoing clinical trials.

StockTitan

Omeros

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

SPDR S&P Biotech

Ark Genomic Revolution ETF

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Novo Nordisk AS

Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026 | OMER Stock News